Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Synaptex LLC
Profile last edited on: 10/11/2019      CAGE: 7NVS2      UEI: SPFEM9CKZKB5

Business Identifier: New class of drug candidates to treat Alzheimer's disease.
Year Founded
----
First Award
2018
Latest Award
2018
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

7905 Vinton Avenue
Lubbock, TX 79424
   N/A
   N/A
   www.synaptexpharma.com
Location: Single
Congr. District: 19
County: Lubbock

Public Profile

Synaptex is structured around the task of successfully tackling Alzheimer's Disease. Recent discoveries by others working in the field suggest how early accumulations of amyloid-beta and tau rapidly can accelerate neurodegeneration. Lead molecules being designed and tested at Syaptex LLC are designed to address halting this process.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$249,507
Phase II Dollars
$0
Total Awarded
$249,507

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2018 1 NIH $249,507
Project Title: Small Molecule Inhibitor Therapeutic Target for Alzheimer's Disease.

Key People / Management

  Philip Jarrett -- Chief Executive Officer

  Ryan Reber -- Director of Management & Fundraising

  Hemachandra Reddy -- Co-Founder and Chief Technology Officer

  P Hemachandra Reddy

Company News

There are no news available.